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ABSTRACT 
The spatial distributions of different types of cells could reveal a cancer cell’s growth pattern, its 
relationships with the tumor microenvironment and the immune response of the body, all of 
which represent key “hallmarks of cancer”. However, manually recognizing and localizing all 
the cells in pathology slides is almost impossible. In this study, we developed an automated cell 
type classification pipeline, ConvPath, which includes nuclei segmentation, convolutional neural 
network-based tumor/stroma/lymphocytes classification, and extraction of tumor 
microenvironment-related features for lung cancer pathology images. The overall classification 
accuracy is 92.9% and 90.1% in training and independent testing datasets, respectively. By 
identifying cells and classifying cell types, this pipeline can convert a pathology image into a 
“spatial map” of tumor/stroma/lymphocyte cells. From this spatial map, we can extract features 
that characterize the tumor micro-environment. Based on these features, we developed an image 
feature-based prognostic model and validated the model in two independent cohorts. The 
predicted risk group serves as an independent prognostic factor, after adjusting for clinical 
variables that include age, gender, smoking status, and stage. ConvPath software is a user-
friendly tool for pathologists and bioinformaticians and is available at 
https://qbrc.swmed.edu/projects/cnn/.  
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Lung cancer is the leading cause of death from cancer, in the United States as well as worldwide. 
Lung adenocarcinoma (ADC) accounts for almost 50% of primary lung malignancies and has 
remarkable heterogeneity in clinical, radiologic, molecular and pathologic features1. The new 
2015 World Health Organization (WHO) histological classifications explicate several subtypes2, 
3. The prognostic and predictive significance of the new ADC subtype classification has been 
verified by pathologist observation in surgical specimens4, 5. However, separating different ADC 
subtypes requires the pathologist to distinguish the subtle morphological patterns of pathology 
slides. This is time-consuming, subjective, and generates considerable inter- and intra-observer 
variation, even with experienced pathologists6.  
With the advance of technology, tumor tissue slide scanning is becoming a routine clinical 
procedure and can produce massive pathological images that capture histological details in high 
resolution. Tumor tissue pathology images not only contain essential information for tumor 
grade and subtype classifications2, but also information on tumor microenvironment and the 
spatial distributions of and interactions among different types of cells. The major cell types in a 
malignant tissue of lung include tumor cells, stroma cells, and lymphocytes. Stromal cells are 
connective tissue cells such as fibroblasts and pericytes, and their interaction with tumor cells 
plays an important role in cancer progression7-9 and metastasis inhibition10. Tumor-infiltrating 
lymphocytes are white blood cells that have migrated into a tumor. They are a mix of different 
types of cells, with T cells being the most abundant population. Tumor-infiltrating lymphocytes 
have been associated with patient prognosis in multiple tumor types11-14. Important information 
can be derived from cell-based image features, such as cell type, cell counts, cell spatial 
distributions and cell-cell interactions. One previous study using this type of feature is by Yuan 
et al15, which discovered that lymphocyte percentages and spatial distribution patterns are 
associated with patient survival. In addition, a more recent study16 used convolutional neural 
network (CNN) to identify lymphocytes and showed that the spatial organization of tumor-
infiltrating lymphocytes (TILs) is associated with patient survival outcome. 
The spatial distributions of different types of cells could reveal a cancer cell’s growth pattern, its 
relationships with the tumor microenvironment and the immune response of the body, all of 
which represent key “hallmarks of cancer”. Cell identification and classification in tumor 
pathology imaging could greatly facilitate the study of cell spatial distributions and their roles in 
tumor progression and metastasis. However, it is impractical for a pathologist to manually 
recognize and localize every individual cell in a pathology slide. Automated cancer pathology 
image recognition systems have been previously used for cancer detection17 and prognostic 
feature extraction18, 19. Deep learning is a modern branch of machine learning; CNN, one of 
several deep learning strategies, performs overwhelmingly in image recognition20-22. CNNs have 
been recently applied in pathology imaging to identify lymphocyte cells16. However, a deep 
learning system which can automatically distinguish tumor, stromal, and lymphocyte cells has 
not been developed yet. 
In this study, an automated image analysis pipeline, ConvPath, was developed for lung ADC 
pathology images. It includes nuclei segmentation, cell type recognition using CNN, and 
extraction of tumor microenvironment-related features (Figure 1). Pathology imaging slides and 
clinical information used in this study were obtained from The Cancer Genome Atlas lung ADC 
project (the TCGA dataset), the National Lung Screening Trial project (the NLST dataset), the 
University of Texas Special Program of Research Excellence (SPORE) in Lung Cancer project 
(the SPORE dataset), and the National Cancer Center/Cancer Hospital of Chinese Academy of 
Medical Sciences, China (the CHCAMS dataset). A prognostic model based on extracted cell-
level image features was developed. The predicted risk score is predictive of overall survival and 
tumor recurrence independent of other clinical features.  
METHODS 
Datasets 
H&E-stained histological images for lung ADC patients and corresponding clinical data were 
collected from four independent cohorts (NLST, TCGA, SPORE, and CHCAMS). The TCGA 
data, including 1337 tumor images from 523 patients, were obtained from the TCGA image 
portal (https://wiki.cancerimagingarchive.net/display/Public/TCGA-LUAD). All TCGA images 
were captured at X20 or X40 magnification and included both frozen and Formalin-Fixed, 
Paraffin-Embedded (FFPE) slides. The NLST data, including 345 tumor images from 201 
patients, were acquired from the National Lung Screening Trial, which was performed by the 
NIH National Cancer Institute. All NLST images were FFPE slides and captured at 40X 
magnification. The CHCAMS data, including 102 images from 102 stage I ADC patients, were 
obtained from the National Cancer Center/Cancer Hospital, Chinese Academy of Medical 
Sciences and Peking Union Medical College (CHCAMS), China. All CHCAMS images were 
FFPE slides and captured at 20X magnification. The SPORE data, including 130 images from 
112 patients, were acquired from the UT Lung SPORE tissue bank. All SPORE images were 
FFPE slides and captured at 20X magnification. The characteristics of the four datasets used in 
this study are summarized in Supplemental Table 3. 
Extraction of image patches centering at nuclei centroids 
A pathologist, Dr. Lin Yang, reviewed the H&E-stained pathology image slides and manually 
labeled ROI boundaries using the annotation tool of ImageScope (Leica Biosystem, Figure 
2a). ROIs were defined by the main malignant area within the pathology images. ConvPath 
randomly selected 10 sampling regions from each selected ROI. The sampling regions were 
sized 5000×5000 or 2500×2500 pixels in 40X or 20X magnification images, respectively. In 
each sampling region, ConvPath further extracted 80×80 image patches centering at nuclei 
centroids (Figure 2b, Supplemental Figure 1).  
In order to extract the image patches, RGB color space was first converted to H&E color space 
with the deconvolution matrix set as [0.550 0.758 0.351; 0.398 0.634 0.600; 0.754 0.077 0.652]23. 
Morphological operations consisting of opening and closing were adopted to process the 
hematoxylin channel image24. Then, ConvPath detected nuclei boundaries using a level set 
segmentation technique25. In this segmentation method, the initial contour was randomly given, 
the value of sigma in Gaussian filter was 1, the number of iterations was 30, and the velocity 
term was 60. Next, nuclei centroids were detected as the moment centroids of connected targets 
in a binary image, where the foreground was the regional maximum locations in a distance map 
of the segmented image. Here, Euclidean distance was utilized for the distance transform and 
regional maximums were searched within 8-connected neighborhoods. Finally, image patches 
using the detected nuclei centroids as centers were extracted from the original pathological RGB 
image (Figure 2b, Supplemental Figure 1). 
Deep learning algorithm in the ConvPath software 
ConvPath incorporates a CNN26-28 to recognize the major cell types, including tumor cells, 
stroma cells and lymphocytes, in the center of pathology image patches (Figure 3a). The input to 
the CNN was an 80x80 image patch normalized to the range [-0.5, 0.5] with 3 channels 
corresponding to the red (R), green (G), and blue (B) channels. The output layer for the CNN 
was a softmax layer with 3 categories: tumor cell, stroma cell, and lymphocyte. For one image 
patch, a probability for each of the 3 categories was predicted by the CNN; the category with the 
highest probability was assigned as the predicted class for the image patch. The CNN was trained 
using a batch size of 10, a momentum of 0.9, a weight decay of 0.0001, an initial learning rate of 
0.01, which shrinks by 0.99995 in each step, and training steps of 20,000. The image patches 
were rotated and flipped to augment sample size. A drop connect probability of 0.5 was used in 
all convolutional layer parameters. The NLST and TCGA datasets were combined and used as 
the training set for the CNN (Figure 3 b&c, Supplemental Table 2), and the SPORE dataset 
was used as the external validation set. The image patches in training and validation sets were 
labeled by the pathologist as ground truth. 
Tumor micro-environment feature extraction.  
Based on the prediction results of the CNN, ConvPath converted the pathology image into a 
“spatial map” of tumor cells, stromal cell and lymphocyte. From this spatial map, we can define 
tumor cells, stromal cell and lymphocyte regions, and characterize the distribution and 
interactions among these regions. Specifically, ConvPath used kernel smoothers to define 
regions of tumor cells, stromal cell and lymphocyte separately within the ROI (Figure 4b). For 
instance, to define the tumor cell region, ConvPath extracted coordinates of the center of all 
image patches and labeled them as 1 if they had been recognized as tumor cells from the 
previous step, 0 if not. For each point on the image, ConvPath then calculated the probability of 
being a tumor cell region by weighting all its neighbors with standard normal density kernel K 
(z/h), where z was defined as the distance between the point and center of each image patch, and 
h, the bandwidth, was defined as 2 times the estimated cell diameter. A region with probability 
larger than 0.5 was defined as a tumor cell region. The same approach was used to define stromal 
cell region and lymphocyte cell region. Next, ConvPath calculated 6 features for each region 
(Supplemental Table 3), which were the perimeter divided by the square root of region area and 
size divided by region area for the 3 kinds of cell regions separately.  
Statistical analysis 
R (version 3.2.4)29 and R packages survival (version 2.38-3), glmnet (version 2.0-5), and clinfun 
(version 1.0.13) were used for statistical analysis. Survival time was defined as period from 
diagnosis to death or last contact for the NLST and TCGA datasets, and from diagnosis to 
recurrence or last contact in the CHCAMS dataset. The prognostic model was trained on the 
NLST patients using a Cox regression model with elastic penalty, to predict a risk score for each 
sampling region. The final risk score of each patient was determined by averaging risk scores 
across 10 sampling regions of this patient. The performance of this prognostic model was 
evaluated on the TCGA and CHCAMS datasets by dichotomizing the patients by the median 
predicted risk score of each dataset. In the validation study, the maximum follow-up time was set 
to six years, since the patient survival after six year may not directly relate to cancer specific 
events. Kaplan-Meier (K-M) plots and log rank tests were used to compare survival outcomes. In 
addition, a multivariate Cox proportional hazard model was used to test whether the prognostic 
risk scores were statistically significant after adjusting for other clinical variables, including age, 
gender, tobacco history, and stage. A Jonckheere-Terpstra (J-T) k-sample test30 was used to test 
whether higher risk scores were correlated with theoretically more severe adenocarcinoma 
subtypes. The results were considered significant if the two-sided (except for J-T test, which is 
one-sided) test p value ≤ 0.05. 
Data availability 
Pathology images and clinical data in the NLST and TCGA datasets that support the findings of 
this study are available online in the NLST (https://biometry.nci.nih.gov/cdas/nlst/) and The 
Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD, 
https://wiki.cancerimagingarchive.net/display/Public/TCGA-LUAD). Data in the SPORE and 
CHCAMS datasets that support the findings of this study are available from the UT Lung 
SPORE Tissue bank and the National Cancer Center/Cancer Hospital, Chinese Academy of 
Medical Sciences and Peking Union Medical College (CHCAMS), China, separately, but 
restrictions apply to the availability of these data.  
Code availability 
The codes are publically accessible via https://qbrc.swmed.edu/projects/cnn/. 
 
RESULTS 
ConvPath classifies lung adenocarcinoma cell types with high accuracy 
11,988 tumor, stromal, and lymphocyte image patches centering at cell nuclei centroids were 
extracted from region of interests (ROIs) in the TCGA and NLST datasets (Figure 2, 
Supplemental Table 3) and used to train the CNN model (Figure 3a). ROIs are regions of the 
slides which contain the majority of malignant tissues (Figure 2a). Example image patches are 
shown in Supplemental Figure 1. The overall classification accuracies of the CNN model on 
training images were 99.3% for lymphocytes, 87.9% for stroma cells, and 91.6% for tumor cells, 
respectively (Figure 3b). The independent cross-study classification rates in the SPORE dataset 
were 97.8% for lymphocytes, 86.5% for stroma cells, and 85.9% for tumor cells (Figure 3c). 
Tumor micro-environment features from predicted sampling regions correlate with overall 
survival 
ConvPath was then used to generate cell type predictions for 10 random sampling regions within 
the ROI on each slide. Based on nuclei centroid locations together with accurate cell type 
predictions (Figure 4a, Supplemental Figure 2), we investigated whether spatial distributions 
of tumor cells, stromal cells, and lymphocytes correlated with the survival outcome of lung ADC 
patients. In each predicted sampling region, tumor, stromal, and lymphocyte cell regions were 
detected using a kernel smoothing algorithm (Figure 4b, Method section). For regions of each 
cell type, simple parameters such as perimeter and size were measured. To ensure comparability 
across image slides captured at different magnitudes, the parameters were normalized by area of 
sampling region. In univariate Cox analysis, 4 of the 6 extracted features significantly correlated 
with survival outcome in the NLST dataset (Supplemental Table 2). Interestingly, both 
perimeter and area of stroma region were good prognostic factors, suggesting a protective effect 
of stroma cells in lung ADC patients (Supplemental Figure 3).  
Development and validation of an image feature-based prognostic model 
Utilizing the region features of each cell type extracted from the pathology images in the NLST 
dataset, we developed a prognostic model to predict patient survival outcome (coefficients of this 
model are shown in Supplemental Table 2). The model was then independently validated in the 
TCGA and CHCAMS datasets. The TCGA and CHCAMS patients were dichotomized according 
to the median predicted risk scores in each dataset. In both datasets, the patients in the predicted 
high-risk group had significantly worse survival outcome than those in the predicted low-risk 
group (Figure 5 a&b, log rank test, p = 0.0047 for the TCGA dataset, p = 0.030 for the 
CHCAMS dataset). To evaluate whether the image features extracted by ConvPath were 
independent of clinical variables, multivariate Cox proportion hazard models were used to adjust 
the predicted risk scores with available clinical variables, including gender, age, stage and 
smoking status (Table 1). After adjustment, the still significant hazard ratios between high- and 
low-risk groups (p = 0.0021 for the TCGA dataset, p = 0.016 for the CHCAMS dataset) 
indicated that risk group as defined by ConvPath-extracted image features was an independent 
prognostic factor, in addition to other clinical variables.  
Predicted risk scores correlate with severity of ADC subtypes 
The 2015 WHO classification of lung cancer further divides invasive lung ADC into several 
subtypes, including acinar, lepidic, micropapillary, papillary, solid, and mucinous ADC2. The 
correlation of the predicted risk scores with predominant histology subtypes identified by our 
pathologist for the CHCAMS dataset, according to the 2015 WHO classification guidelines, was 
tested (Figure 5c). Higher risk scores correlated with more aggressive ADC subtypes, such as 
solid predominant ADC and invasive mucinous ADC (p = 0.0039).  
The ConvPath software and web server 
To facilitate practical application of this pathological image analysis pipeline by pathologists and 
bioinformaticians, the image segmentation, deep learning, and feature extraction algorithms were 
incorporated into the ConvPath software. The ConvPath software is publicly accessible from the 
web server created for this study, which is at https://qbrc.swmed.edu/projects/cnn/ 
(Supplemental Figure 6). 
DISCUSSION 
In this study, an image analysis and cell classification pipeline was developed. It can perform 
nuclei segmentation, CCN based cell type prediction, and feature extraction (Figure 1). This 
pipeline successfully visualizes the spatial distributions of tumor, stromal, and lymphocyte cells 
in ROI of lung ADC pathology images. It can potentially serve as a prognostic method 
independent of other clinical variables. The patient prognostic model based on extracted image 
features was trained in the NLST dataset and independently validated in the TCGA and 
CHCAMS datasets, which indicates the generalizability of this analysis pipeline to other lung 
ADC patients. 
The accurate classification of cell types in pathology images was validated in an independent 
data cohort. While the qualities of H&E staining vary across different cohorts and there are 
inherent inter-patient differences, ConvPath still has 90.1% overall accuracy in the SPORE 
dataset (Figure 3c). The robustness of ConvPath benefits from the level set-based segmentation 
algorithm in the nuclei segmentation step. This segmentation algorithm is invariant to the 
location of initial contour and can handle high variability across different H&E pathology 
images. Moreover, nuclei centroid extraction based on distance transform can separate most of 
the connected nuclei that are not properly processed by the commonly used CellProfiler 
software19, 31. The robustness of prediction also benefits from the powerful CNN, which is 
designed to emulate the behavior of the visual cortex, and poses properties of deep structure, 
local connectivity, and shared weights.  
The relationships between the extracted tumor micro-environment-related image features and 
patient prognosis were evaluated in this study (Supplemental Table 2). In univariate analysis, 
higher stromal cell abundance correlated with better prognosis (Supplemental Figure 4), which 
is consistent with a recent report on lung ADC patients10. However, controversial roles of stroma 
cells in tumor progression have been reported, including stimulation of tumor proliferation 
through growth signals and limitation of tumor cells metastatic spreading8, 9, 32. Combinatory 
analysis of cell spatial distribution detected in this study and the functionality of stroma cells, 
which could not be evaluated through H&E staining, will help answer whether these 
controversial roles arise from the different activation status of crosstalk between tumor and 
stroma. In contrast, higher lymphocyte abundance, reflected by region size rather than perimeter, 
correlated with worse prognosis (Supplemental Table 2, Supplemental Figure 5). However, 
although the presence of both tumor- and stroma-infiltrating lymphocytes has been reported to 
correlate with tumor cell apoptosis and better patient survival in non-small cell lung cancer11, 14, 
33, the tumor-suppressive or tumor-promoting properties of lymphocytes depend on the tumor 
microenvironment34. Thus, quantifying distribution and interaction with tumor or stroma cells of 
lymphocytes can potentially provide a way to evaluate immune response status and serve as a 
biomarker for immunotherapy response. 
The goal of this study is to develop software tools to automatically identify cells and classify cell 
types in tumor pathology image. Since there are more than 10,000 cells in each sampling region 
(Supplemental Figure 2), it is extremely labor-intensive and error-prone to manually localize 
and label each cell nuclei. Thus, automatic visualization of distributions of different cell types 
will facilitate the diagnostic procedure. More importantly, extracting image features directly 
from the labeled sampling region allows for accurate quantification of tumor, stroma, and 
lymphocyte regions, which can avoid subjective assessment by human pathologists. In addition, 
this study provides an automatic and quantitative tool to dissect intra-tumor heterogeneity on the 
cell-type level, which has been reported to inform metastasis35, immunotherapy responsiveness36, 
and angiogenesis inhibitor responsiveness37. The analysis pipeline developed in this study could 
convert the pathology image into a “spatial map” of tumor cells, stromal cells and lymphocytes. 
This will greatly facilitate and empower comprehensive spatial analysis of cell distributions and 
interactions, as well as their roles in tumor progression and metastasis.  
There are several limitations of the ConvPath pathology image analysis pipeline. First, the 
sampling region selection and subsequent steps rely on ROI labeling, which is currently done by 
pathologists. We are working on fully automated ROI selection, which will further decrease the 
bias caused by subjectivity. Second, only three major cell types are considered in the ConvPath 
CNN algorithm; thus, this CNN model is sensitive to out-of-focus cell types such as 
macrophages and epithelial cells. Also, different subtypes of lymphocytes, such as CD4+ and 
CD8+ T cells, are not distinguishable using our algorithm11, 38. More comprehensive labeling and 
immunohistochemical staining will help solve this problem. Third, more comprehensive analysis 
of spatial distribution of cells is not included in this research37, 39. Analyzing the spatial patterns, 
such as cell clustering and inter-cell interactions, will help us understand the mechanism of 
tumor progression and immune response to tumor cells. 
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Table 1. Multivariate analysis of the predicted risk scores in the CHCAMS and TCGA datasets 
adjusted by clinical variables. 
TCGA dataset (n=346) HR 95% CI p value 
High risk vs. low risk 2.19 (1.33-3.60) 0.0021 
Age (per year) 1.03 (1.01-1.06) 0.014 
Male vs. female 0.69 (1.45-1.16) 0.16 
Smoker vs. non-smoker 0.88 (0.53-1.47) 0.62 
Stage    
    Stage I ref  - 
    Stage II 2.69 (1.45-5.00) 0.0017 
    Stage III 5.04 (2.69-9.43) <0.001 
    Stage IV 6.06 (2.49-14.73) <0.001 
CHCAMS dataset (n=88) HR 95% CI p value 
High risk vs. low risk 2.21 1.16-4.21 0.016 
Age (per year) 1.02 0.99-1.06 0.202 
Male vs. female 1.85 0.69-4.91 0.22 
Smoker vs. non-smoker 0.76 0.28-2.04 0.585 
 
  
 CHCAMS, National Cancer Center/Cancer Hospital of Chinese Academy of Medical Sciences, 
China; CI, confidence interval; HR, hazard ratio; TCGA, The Cancer Genome Atlas. Figure 1. 
Flow chart of ConvPath-aided pathological image analysis. 
  
 Figure 2. Image preprocessing step of the ConvPath software. (a) Selection of regions of interest 
(ROIs) in whole pathological imaging slides. (b) Image segmentation pipeline to extract cell-
centered image patches from selected ROIs. 
  
Figure 3. Cell type recognition step of the ConvPath software. (a) Schema and structure of the 
convolutional neural network (CNN) to recognize the types of cells in the centers of image 
patches. (b) Confusion matrix of internal testing results of CNN on the NLST and TCGA 
training image slides. Prediction accuracies are calculated based on 3996 image patches for each 
cell type. (c) Confusion matrix of independent testing results of CNN on image patches of the 
SPORE dataset. Prediction accuracies are calculated based on 8245 lymphocyte, 2211 stroma, 
and 6836 tumor patches. 
  
Figure 4. Feature extraction step of the ConvPath software. (a) A zoomed-in part of a sampling 
region (Supplemental Figure 3) in which cell nuclei centroids are labeled with predicted cell 
types. Green, stroma; cyan, lymphocyte; yellow, tumor. (b) Cell type region detection using a 
kernel smoothing algorithm for the sampling region shown in Supplemental Figure 3. Area and 
perimeters are evaluated for regions of tumor, stroma, and lymphocyte. 
  
 Figure 5. Application of the prognostic model to independent datasets. (a, b) Validation of the 
prognostic model in the TCGA overall survival data (a, log rank test, p = 0.0047) and the 
CHCAMS recurrence data (b, log rank test, p = 0.030). (c) Distribution of predicted risk scores 
in the 5 histological subtypes of lung adenocarcinoma for the CHCAMS dataset patients. 
Jonckheere-Terpstra k-sample test, p = 0.0039. 
  
SUPPLEMENTAL MATERIAL 
Supplemental Table1. Patient population characteristics for TCGA, NLST, CHCAMS and 
SPORE datasets. 
Cohort TCGA NLST Beijing SPORE 
Number of patients 523 201 102  112 
Number of slides (Tumor) 1337 345 102 130 
Age at diagnosis (years, median [LQ-HQ]) 66 [59-73] 64 [60-68] 59 [54-66] 65 [58-73] 
Follow-up (years, median [LQ-HQ]) 0.6 [0.1-2.0] 6.6 [5.4-6.9] 5.0 [4.1-5.8] 3.3 [1.7-5.3] 
Vital status (%) Alive 394 (75.3) 136 (67.7) 74 (72.5) 75 (67.0) 
Deceased 126 (24.1) 64 (31.8) 28(27.5) 37 (33.0) 
NA 3 (0.6) 1 (0.5) 0 (0.0) 0 (0.0) 
Gender (%) M 242(46.3) 112 (55.7) 46 (45.1) 56 (50.0) 
F 278 (53.2) 89 (44.3) 56 (54.9) 56 (50.0) 
NA 3 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 
Cancer stage (%) I 135 (67.7) 135 (67.2) 102 (100.0) 70 (62.5) 
II 20 (9.9) 20 (10.0) 0 (0.0) 17 (15.2) 
III 33 (16.4) 33 (16.4) 0 (0.0) 24 (21.4) 
IV 13 (6.5) 13 (6.5) 0 (0.0) 1 (0.9) 
NA 4 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 
Smoking status 
(%) 
Smoker 431 (82.4) 110 (54.7) 43 (42.2) 98 (87.5) 
Non-smoker 75 (14.3) 91 (45.3) 59 (57.8) 13 (11.6) 
NA 17 (3.3) 0 (0.0) 0 (0.0) 1 (0.9) 
CHCAMS, National Cancer Center/Cancer Hospital of Chinese Academy of Medical Sciences, China; 
HQ, higher quantile at 75%; LQ, lower quantile at 25%; NLST, the National Lung Screening Trial; 
TCGA, The Cancer Genome Atlas.  
Supplemental Table 2. Breakdown of the numbers of image patches from each training dataset 
for the deep learning algorithm in ConvPath. 
Data source Cell type # image patch 
NLST lymphocyte 2096 
NLST stroma 2550 
NLST tumor 1298 
TCGA lymphocyte 1900 
TCGA stroma 1446 
TCGA tumor 2698 
NLST, the National Lung Screening Trial; TCGA, The Cancer Genome Atlas.  
Supplemental Table 3. Extracted cell type-level image features with their data distribution, 
explanation, and univariate analysis results in the NLST dataset.  
 
Univariate in the 
NLST dataset 
Glmnet 
model Data range, median (min - max) 
Features HR p value 
Coef.  
(λ = 0.02*) NLST TCGA CHCAMS 
Perimeter of lymphocyte cell 
region/square root of image size† 1.006 0.30 -0.0019 
4.92 
(0 - 23.04) 
0.2 
(0 - 18.5) 
0.14 
(0 - 13.15) 
Perimeter of stromal cell 
region/square root of image size 0.97 < 0.001 -0.015 
6.47 
(0 - 23.51) 
9.95  
(0 - 26.62) 
13.38 
(0 - 25.24) 
Perimeter of tumor cell 
region/square root of image size 0.98 0.0016 -0.014 
13.4 
(0 - 26.6) 
11.99 
(0 - 26.04) 
14 
(0 - 26.61) 
Size of lymphocyte cell 
region/image size 1.63 0.0012 0.26 
0.08 
(0 - 1) 
0 
(0 - 0.72) 
0 
(0 - 1) 
Size of stromal cell region/image 
size 0.53 < 0.001 -0.16 
0.1 
(0 - 0.94) 
0.19 
(0 - 1) 
0.3 
(0 - 0.98) 
Size of tumor cell region/image 
size 0.96 0.71 -0.060 
0.61 
(0 - 1) 
0.66 
(0 - 1) 
0.55 
(0 - 1) 
CHCAMS, National Cancer Center/Cancer Hospital of Chinese Academy of Medical Sciences, China; 
Coef., coefficient; HR, hazard ratio; NLST, the National Lung Screening Trial; TCGA, The Cancer 
Genome Atlas. 
* λ is the penalty coefficient in the glmnet model. Its value has been optimized by 10-fold cross-
validation. 
† Image here refers to the square sampling region.  
Supplemental Figure 1. Example 80×80 pixels image patches centering at cell nuclei centroids.  
  
Supplemental Figure 2. A sampling region in H&E-staining slide on which all cells are color-
labeled by CNN predictions. Green, stroma; cyan, lymphocyte; yellow, tumor. The red rectangle 
is enlarged and shown in Figure 4a.  
  
  
(a)                                                                       (b) 
  
(c)                                                                       (d) 
Supplemental Figure 3. Examples of original sampling regions (a&c, left panels) and the 
regions labeled by ConvPath (b&d, right panels). Exemplar images in which there are few 
stroma cells or lymphocytes. Yellow, tumor cells; green, stroma cells; blue, lymphocytes.   
   
(a)                                                                       (b) 
  
(c)                                                                       (d) 
Supplemental Figure 4. Examples of original sampling regions (a&c, left panels) and the 
regions labeled by ConvPath (b&d, right panels). Exemplar images in which tumor cells are 
surrounded with stroma cells. Yellow, tumor cells; green, stroma cells; blue, lymphocytes.   
  
(a)                                                                       (b) 
  
(c)                                                                       (d) 
Supplemental Figure 5. Examples of original sampling regions (a&c, left panels) and the 
regions labeled by ConvPath (b&d, right panels). Exemplar images in which there are 
lymphocyte infiltration. Yellow, tumor cells; green, stroma cells; blue, lymphocytes.   
Supplemental Figure 6. Screenshot of the webserver from which potential users can download 
source codes, sample test data, and user manual explaining usage of ConvPath. 
(https://qbrc.swmed.edu/projects/cnn/). 
 
 
 
